SmithKline Beecham says that it has received marketing clearance fromthe Chinese Ministry of Health for a transdermal nicotine patch for smoking cessation, having already licensed the patch from Alza Corp for commercialization in most countries in the world. SB's chief operating officer Jean-Pierre Garnier pointed out that China has the most smokers of any nation in the world and that the company is committed to expanding the global market for smoking cessation products.
SB Acquires Another Patch SB has also reached agreement with Hoechst Marion Roussel and Alza to acquire the nicotine patch Nicabate in Australia. It is the best-selling patch of its type in the USA, and HMR and Alza will continue to market the product there, where it is sold under the brand name Nicoderm CO. Mitch Cybulski, SB International's chairman, said that recent regulatory changes have allowed greater consumer access to the smoking control products in Australia, adding that the company "is in a unique position" to expand the markets there.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze